Non-nucleoside benzimidazole-based allosteric inhibitors of the hepatitis C virus NS5B polymerase: Inhibition of subgenomic hepatitis C virus RNA replicons in huh-7 cells

Journal of Medicinal Chemistry

Volumn 47, Issue 27, 2004, Pages 6884-6892

  Beaulieu, Pierre L ^a   Bousquet, Yves ^a   Gauthier, Jean ^a   Gillard, James ^a   Marquis, Martin ^a   McKercher, Ginette ^a   Pellerin, Charles ^a   Valois, Serge ^a   Kukolj, George ^a  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; CILUPREVIR; ENZYME INHIBITOR; HEPATITIS C VIRUS NS5B POLYMERASE; TRYPTOPHAN DERIVATIVE; UNCLASSIFIED DRUG; VIRUS ENZYME; VIRUS RNA;

ALLOSTERISM; ANTIVIRAL ACTIVITY; ARTICLE; CELL ASSAY; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG POTENCY; ENZYME INHIBITION; EX VIVO STUDY; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PHYSICAL CHEMISTRY; PROCESS MODEL; PROCESS OPTIMIZATION; REPLICON; VALIDATION PROCESS; VIRUS INHIBITION; VIRUS REPLICATION;

ALLOSTERIC REGULATION; ANTIVIRAL AGENTS; BENZIMIDAZOLES; ENZYME INHIBITORS; HEPACIVIRUS; HUMANS; REPLICON; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS;

EID: 11144220783     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040134d     Document Type: Article

References (35)

1. Choo, Q.-L.; Kuo G.; Weiner, A. J.; Overby, L. R.; Bradley, D. W.; Houghton, M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244, 359-362.
2. (a) Di Bisceglie, A. M. Lancet 1998, 351, 351.
3. (b) World Health Organization; Hepatitis C. Seroprevalance of hepatitis C virus (HCV) in a population sample, Wkly. Epidemiol. Rec. 1996, 71, 346.
4. (c) NIH Consensus Statements; Management of Hepatitis C 2002, 19 (1).
5. (a) Di Bisceglie, A. M.; Hoofnagle, J. H. Optimal therapy of hepatitis C. Hepatology 2002, 36 (suppl. 1), S121-S127.
6. (b) Chandler, G.; Sulkowski, M. S.; Jenckes, M. W.; Torbenson, M. S.; Herlong, H. F.; Bass, E. B.; Gebo, K. A. Treatment of chronic hepatitis C: A systematic review. Hepatology 2002, 36, S135-S144.
7. Scott, J. J.; Perry, C. M. Interferon-α-2b plus ribavarin. A review of its use in the management of chronic hepatitis C. Drugs 2002, 62, 507-556.
8. Beaulieu, P. L.; Llinàs-Brunet, M. Therapies for Hepatitis C infection: Targeting the nonstructural proteins of HCV. Curr. Med. Chem-Anti-Infective Agents 2002, 1, 163-176.
9. (a) Reed, K. E.; Rice, C. M. Curr. Top. Microbiol. Immunol. 2000, 242, 55.
10. (b) Kolykhalov, A. A.; Mihalik, K.; Feinstone, S. M.; Rice, C. M. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo. J. Virol. 2000, 74, 2046-2051.
11. McPhee, F.; Yeung, K.-S.; Good, A. C.; Meanwell, N. A. Hepatitis C virus NS3 serine protease as a discovery target. Drugs Future 2003, 28, 465-488.
12. (a) Hinrichsen, H.; Benhamou, Y.; Wedemeyer, H.; Reiser, M.; Sentjens, R. E.; Calleja, J. L.; Forns, X.; Erhardt, A.; Cröenlein, J.; Chaves, R.; Yong, C.-L.; Nehmiz, G.; Steinmann, G. G. Short-term antiviral efficacy of BILN 2061, a HCV serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004,127, 1347-1355.
13. (b) Lamarre, D.; Anderson, P. C.; Bailey, M.; Beaulieu, P.; Bolger, G.; Bonneau, P.; Bös, M.; Cameron, D. R.; Cartier, M.; Cordingley, M. G.; Faucher, A.-M.; Goudreau, N.; Kawai, S. H.; Kukolj, G.; Lagacé, L.; LaPlante, s. R.; Narjes, H.; Poupart, M.-A.; Rancourt, J.; Sentjens, R. E.; St George, R.; Simoneau, B.; Steinmann, G.; Thibeault, D.; Tsantrizos, Y.; Weldpn, S. M.; Yong, C.-L.; Llinàs-Brunet, M. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003, 426, 186-189.
14. (a) Lohmann, V.; Körner, F.; Koch, J. O.; Herian, U.; Theilmann, L.; Bartenschlager, R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285, 110-113.
15. Animal models for HCV replication have been developed, but they are not readily available or amenable for routine compound testing: (b) Lanford, R. E.; Bigger, C.; Bassett, S.; Klimpel G. The chimpanzee model of hepatitis C virus infection. ILAR J. 2001, 42, 117-126.
16. (c) Grakoui, A.; Hanson, H. L.; Rice, C. M. Bad time for Bonzo? Experimental models of hepatitis C virus infection, replication, and pathogenesis. Hepatology 2001, 33, 489-495.
17. (d) Mercer, D. F.; Schiller, D. E.; Elliott, J. F.; Douglas, D. N.; Hao, C.; Rinfret, A.; Addison, W. R.; Fisher, K. P.; Churchill, T. A.; Lakey, J. R. T.; Tyrrell, D. L. J.; Kneteman, N. M. Hepatitis C virus replication in mice with chimeric human livers. Nature Medicine 2001, 7, 927-933.
18. Beaulieu, P. L.; Tsantrizos, Y. S. Inhibitors of the HCV NS5B polymerase: new hope for the treatment of hepatitis C infections. Curr. Opin. Invest. Drugs 2004, 5, 838-850.
19. McKercher, G.; Beaulieu, P. L.; Lamarre, D.; LaPlante, S.; Lefebvre, S.; Pellerin, C.; Thauvette, L.; Kukolj, G. Specific inhibitors of HCV polymerase identified using an NS5B with lower affinity for template/primer substrate. Nucleic Acids Res. 2004, 32, 422-431.
20. Beaulieu, P. L.; Bös, M.; Bousquet, Y.; Fazal, G.; Gauthier, J.; Gillard, J.; Goulet, S.; LaPlante, S.; Poupart, M.-A.; Lefebvre, S.; McKercher, G.; Pellerin, C.; Austel, V.; Kukolj, G. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: Discovery and preliminary SAR of benzimidazole derivatives. Bioorg. Med. Chem. Lett. 2004, 14, 119-124.
21. Beaulieu P. L.; Bös, M.; Bousquet, Y.; DeRoy, P.; Fazal, G.; Gauthier, J.; Gillard, J.; Goulet, S.; McKercher, G.; Poupart, M.-A.; Valois, S.; G.; Kukolj. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: Discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency. Bioorg. Med. Chem. Lett. 2004, 14, 967-971.
22. Tomei, L.; Altamura, S.; Bartholomew, L.; Biroccio, A.; Ceccacci, A.; Pacini, L.; Narjes, F.; Gennari, N.; Bisbocci, M.; Incitti, I.; Orsatti, L.; Harper, S.; Stanfield, L; Rowley, M.; De Francesco, R.; Migliaccio, G. Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J. Virol. 2003, 77, 13225-13231.
23. log Doct/buffer values were measured in octanol-100 mM phosphate buffer (pH 7.2) by the shaking-flask method.
24. Total replicon RNA levels were normalized to control cellular GAPDH mRNA. We also verified that ester 5 was chemically stable under assay conditions, and hydrolysis to acid 4 was not detected.
25. LaPlante, S.; Jakalian, A.; Aubry, N.; Bousquet, Y.; Ferland, J.-M.; Gillard, J.; Lefebvre, S.; Poirier, M.; Tsantrizos, Y.; Kukolj, G.; Beaulieu, P. L. Binding mode of benzimidazole inhibitors of the hepatitis C virus RNA polymerase, Angew. Chem. 2004, 43, 4306-4311.
26. Activity in the replicon was recently reported for related benzimidazole-based inhibitors developed by Japan Tobacco Co. that are similar to compound 2, but the small furyl substituent at C-2 was replaced by a large lipophilic group that provides only modest increases in intrinsic potency but presumably improves cellular permeation; see ref 14.
27. (a) Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
28. (b) Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44, 235-249.
29. (c) Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45, 2615-2623.
30. Wiley, D. C.; England, D. C.; Behr, L. C. The preparation of thiazoles. Org. Reactions 1951, 6, 367-409.
31. Beaulieu, P. L.; Haché, B.; von Moos, E. A practical oxone-mediated, high-throughput, solution-phase synthesis of benzimidazoles from 1,2-phenylenediamines and aldehydes and its application to preparative scale synthesis. Synthesis 2003, 1683-1692.
32. Pozdnev, V. F. Teri-butyloxycarbonylation of tyrosine and other phenolic amino acids by di-tert-butyl pyrocarbonate. Chem. Nat. Compd. (Engl. Transl.) 1982, 18, 125-126.
33. Hydroxy-1-methyl-L-tryptophan was prepared from benzyl (2S)-N-benzyloxycarbonyl-2-aziridinecarboxylate and 5-benzyloxy-1-methylindole with the following procedure: Bennani, Y. L.; Zhu, G.-D.; Freeman, J. C. Scandium-mediated opening of aziridine carboxylates: A facile synthesis of aryl substituted tryptophans. Synlett 1998, 754-756. The amino acid was protected as the methyl ester using thionyl chloride-MeOH prior to coupling.
34. Knorr, R.; Trzeciak, A.; Bannwarth, W.; Gillessen, D. New coupling reagents in peptide chemistry. Tetrahedron Lett. 1989, 30, 1927-1930.
35. Beaulieu, P. L.; Fazal, G.; Goulet, S.; Kukolj, G.; Poirier, M.; Tsantrizos, Y.; Jolicoeur, E.; Gillard, J.; Poupart, M.-A.; Rancourt, J. WO Patent WO 03/010141, 2003.